Previous small clinical trials found that atorvastatin decreases ALT serum levels while improving hepatic steatosis [276], and that rosuvastatin reduces both ALT and AST serum levels with amelioration of liver fibrosis [277]. This evidence concerns the gene GPT and fatty liver disease.